The first part of our research focused on whether the studied genes were differentially expressed between the primary tumors for which they were identified and their NATs (RNF135 and EFNB2 for HCC, RNF125, ABLIM1 and HOXC4 for CCA, OSMR and LIFR-AS1 for OSMR and PROX1-AS1 for PDAC). This evidence concerns the gene PROX1 and cholangiocarcinoma.